

TAB 3

K 043607

# 510(K) SUMMARY OF SAFETY & EFFECTIVENESS

Official Contact

Zita A. Yurko

Manager, Regulatory Affairs/Product Assurance

Respironics, Inc.

1001 Murry Ridge Lane Murrysville, PA 15668

724-387-4120 724-387-4206 (fax)

Email: Zita.Yurko@Respironics.com

**Classification Reference** 

21 CFR 868.5905

**Product Code** 

BZD – Non-Continuous ventilator

Common/Usual Name

**CPAP System** 

**Proprietary Name** 

Respironics BiPAP Pro 2 Bi-level System with Bi-Flex

Predicate Device(s)

Respironics BiPAP Pro 2 Bi-level System (K032834)

Respironics BiPAP Synchrony Ventilatory Support System (K012323)

Reason for submission

Modified design.

### **Substantial Equivalence**

The modified device has the following similarities to the previously cleared predicate devices:

Same intended use.

Same operating principle.

Same technology.

Same manufacturing process.

Design verification tests were performed on the Respironics BiPAP Pro 2 Bi-level System as a result of the risk analysis and product requirements. All tests were verified to meet the required acceptance criteria. Respironics has determined that the modifications have no impact on the safety and effectiveness of the device. In summary, the device described in this submission is substantially equivalent to the predicate devices.

The modified device complies with the applicable standards referenced in the Guidance for FDA Reviewers and Industry "Guidance for the Content of Pre-market Submissions for Software Contained in Medical Devices," May 1998.

### Intended Use

The Respironics BiPAP Pro 2 Bi-level System delivers positive airway pressure therapy for the treatment of Obstructive Sleep Apnea only. For use in the home or hospital/institutional environment on adult patients.

## **Device Description**

The Respironics BiPAP Pro 2 Bi-level System is a microprocessor controlled blower based bi-level positive pressure system that delivers two different positive pressure levels (IPAP/EPAP). The dual pressure levels provide a more natural means of delivering pressure support therapy to the patient resulting in improved patient comfort. The BiPAP Pro 2 Bi-level System also includes the flex therapy feature cleared in K032834 which provides the patient with additional comfort by easing the transition from the end of inspiration to the beginning of exhalation. This clearance is seeking to extend the Bi-Flex range from 20 to 25 cmH2O maximum, to provide remote control of the device in a clinical setting and to allow viewing of compliance data by a physician/clinician. Like its predicates, the BiPAP Pro 2 Bi-level System is intended for use with a patient circuit that is used to connect the device to the

32

patient interface device (mask). A typical patient circuit consists of a six-foot disposable or reusable smooth lumen 22mm tubing, an exhalation device, and a patient interface device.



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

JAN 2 8 2005

Ms. Zita A. Yurko Manager, Regulatory Affairs/Product Assurance Respironics, Incorporated 1001 Murry Ridge Lane Murrysville, Pennsylvania 15668

Re: K043607

Trade/Device Name: Respironics BiPAP Pro 2 Bi-level System with Bi-Flex

Regulation Number: 21 CFR 868.5905

Regulation Name: Noncontinuous Ventilator (IPPB)

Regulatory Class: II Product Code: BZD

Dated: December 29, 2004 Received: December 30, 2004

#### Dear Ms. Yurko:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <a href="http://www.fda.gov/cdrh/industry/support/index.html">http://www.fda.gov/cdrh/industry/support/index.html</a>.

Sincerely yours,

omu Lin, i ii.

Director

Division of Anesthesiology, General Hospital, Infection Control and Dental Devices Office of Device Evaluation

Center for Devices and

Radiological Health

510(k) Number (if known): **4043667** 

Device Name: Respironics BiPAP Pro 2 Bi-level System with Bi-Flex

### Intended Use/Indications for Use

The Respironics BiPAP Pro 2 Bi-level System with Bi-Flex delivers positive airway pressure therapy for the treatment of Obstructive Sleep Apnea only.

### **Environment of Use/Patient Population**

For use in the home or hospital/institutional environment on adult patients.

Prescription Use	<u> </u>	OR	Over-The-Counter Use
(Per 21 CFR 801.10	09)		(Optional Format 1-2-96)
(PLEASE DO NOT	WRITE BE	LOW THIS LINE - CONT	INUE ON ANOTHER PAGE IF NEEDED)
	Conct	 urrence of CDRH, Office of	f Device Evaluation (ODE)

(Division Sign-Off)

Division of Anesthesiology, General Hospital, Insection Control, Dental Devices

510(k) Number K043607